x

Posted 03 November, 2023

Morphic Holding, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:MORF in a 8-K filed on 03 November, 2023.


  As previously announced on September 26, 2023, Praveen P. Tipirneni, M.D., the Company's Chief Executive Officer and a member of the Company's board of directors (the "Board"), is taking a temporary medical leave of absence from his role as Chief Executive Officer. In connection with Dr. Tipirneni's leave of absence, effective November 1, 2023, the Board has appointed Bruce N. Rogers, Ph.D., the Company's President, as the Company's interim principal executive officer until Dr. Tipirneni's return.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Morphic Holding, Inc.
Health Care/Life Sciences • Biotechnology
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
Market Cap
$1.89B
View Company Details
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer; Compensatory Arrangements of Certain Officers.

As previously announced on September 26, 2023, Praveen P. Tipirneni, M.D., the Company's Chief Executive Officer and a member of the Company's board of directors (the "Board"), is taking a temporary medical leave of absence from his role as Chief Executive Officer. In connection with Dr. Tipirneni's leave of absence, effective November 1, 2023, the Board has appointed Bruce N. Rogers, Ph.D., the Company's President, as the Company's interim principal executive officer until Dr. Tipirneni's return. Dr. Rogers continues to serve as the Company's President during this interim period.